イリノイ州の薬局技師の職業疲労を調査する: テーマ分析
Sodam Kim1, Johnson Osei1, Grace Fick1
1Department of Pharmacy Systems and Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, United States.
Research in social & administrative pharmacy : RSAP
|February 21, 2026
まとめ
薬局技師は,作業システム要因による職業疲労を経験します. 人的要因,作業量,組織的なサポートに対応する介入が技術者の福祉と患者の成果を改善するために必要です.
科学分野:
- 薬局の実践について
- 職業衛生は,健康に関するものです.
- ヒューマン・ファクターズ・エンジニアリング
背景:
- 患者の安全は国家優先事項ですが,医療従事者の福祉,特に薬局技師の福祉はしばしば見過ごされています.
- 薬局技師の職業的疲労は,医薬品の安全性および患者ケアにおける重要な役割にもかかわらず,認識されていない.
- 職業疲労に関する既存の研究は,薬局技術者が直面するユニークな課題に十分に対処していない.
研究 の 目的:
- 薬局技師の職業疲労に関する主観的な経験を調査する.
- イリノイ州のコミュニティ薬局技術者の疲労を軽減または軽減する特定の作業システムコンポーネントを特定します.
- 薬局技師の労働力における職業疲労の理解のギャップを埋めるために.
主な方法:
- 定量調査と質的半構造面接を組み合わせた混合方法のアプローチ.
- 労働疲労の概念的枠組みと患者の安全のためのシステムエンジニアリングイニシアチブを利用しました.
- 定性データに対する演的なテーマ分析による横断的観測設計を採用した.
主要な成果:
- 5つの主要なテーマが浮上した:人間的要因,休憩と作業量の影響,組織と技術者の価値観,支援インフラ,仕事生活の質と患者の結果との関連.
- 人間の要因は,疲労の悪化と緩和の両方に重要な貢献者として特定されました.
- 高い作業負荷は,技術者が必要な休憩を取ることをしばしば妨げていたが,休憩は疲労を減らすものとして認識されている.
結論:
- 職業的疲労は,複数の作業システム要素の影響を受け,コミュニティ製薬の技術者にとって重要な問題です.
- 特定されたテーマは,疲労を軽減するためのターゲットを絞った介入の開発のための基盤を提供します.
- 薬局技師の職業疲労に対処することは,労働力の福祉と患者の安全の両方を高めるために不可欠です.
関連する概念動画
Interdisciplinary Care: The Health Care Team-II
2.3K
An interdisciplinary team includes many healthcare professionals working together and utilizing their skills, knowledge, and expertise to provide holistic and quality patient care. Here are a few more healthcare professionals.
Physical Therapist
A physical therapist (PT) aims to restore function or prevent additional impairment in a patient following an injury or disease. Massage, heat, cold, water, sonar waves, exercises, and electrical stimulation are some treatments used by PTs to treat...
Physical Therapist
A physical therapist (PT) aims to restore function or prevent additional impairment in a patient following an injury or disease. Massage, heat, cold, water, sonar waves, exercises, and electrical stimulation are some treatments used by PTs to treat...
2.3K
Methods of Documentation II: POMR
1.5K
The Problem-Oriented Medical Record (POMR) revolutionized medical record-keeping by introducing a systematic approach focusing on the patient's problems rather than merely listing symptoms. Dr. Lawrence Weed's introduction of this method in the 1960s marked a significant advancement in medical documentation. The POMR framework consists of four key components: the database, problem list, plan of care, and progress notes.
1.5K
Pharmaceutical Poisoning: Potential Scenarios
22
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
22
Fatigue
885
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
885
Therapeutic Drug Monitoring: Drug Analysis Methods
231
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
231
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
198
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
198


